High Altitude Pulmonary Edema: An Update on Omics Data and Redefining Susceptibility
Peptide and Proteomics Division, Defence Institute of Physiology and Allied Sciences, Defence Research and Development Organization, Lucknow Road, Timarpur, Delhi -110054, India
- *Corresponding Author:
- Yasmin Ahmad
Peptide and Proteomics
Defence Institute of Physiology & Allied Science (DIPAS)
Defence Research & Development Organization (DRDO)
Ministry of Defence, Delhi, India
E-mail: [email protected]
Received date: April 21, 2015; Accepted date: May 28, 2015; Published date: June 03, 2015
Citation: Paul S, Gangwar A, Arya A, Bhargava K, Ahmad Y (2015) High Altitude Pulmonary Edema: An Update on Omics Data and Redefining Susceptibility. J Proteomics Bioinform 8:116-125.doi:10.4172/jpb.1000359
Copyright: © 2015 Paul S, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
High altitude pulmonary edema (HAPE) is a serious pathological condition associated with rapid ascent to high altitude occurring in non-acclimatized but otherwise healthy individuals. Decades of scientific studies on HAPE have unraveled the disease pathology, diagnosis and therapeutic interventions yet, the etiology is still unknown. A vast scientific literature is available on HAPE for a quick reference of clinicians, researchers and academicians. Perhaps, the view of mountain travelers is different and their anticipation of HAPE susceptibility comprises of personal experience. Ever-increasing number of visitors to high altitude demands the possibility of HAPE susceptibility screening, however, scientific community is yet to find a staunch solution. This review is an update of recent information on HAPE susceptibility indicators from genomics, proteomics and metabolomics as well as information pertaining to treatment/prognosis of HAPE.